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Abstract
Inherited susceptibility to rheumatoid arthritis (RA) is asociated with the DRB1 genes
encoding the human leukocyte antigen (HLA)-DR4 and HLA-DR1 molecules. Transgenic
mice expressing these major histocompatibility complex (MHC) class II molecules have been
developed to generate humanized models for RA. The relevance of these models for
understanding RA will be discussed.
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Introduction
More than 20 years ago, Stastny [1] reported that
HLA-DR4 is associated with RA. Nine years later,
Gregersen  et al [2] proposed the shared epitope (SE)
hypothesis based on the observation that the RA-associ-
ated DRB1 alleles encode a common sequence of amino
acids corresponding to residues 67–74. Several SE-posi-
tive (SE+) DRB1 alleles have since been reported to be
associated with RA and include the DR4 subtypes
DRB1*0401, *0404, *0405 and *0408 as well as the
DRB1*0101, *1402, and *1001 alleles. Nepom [3] has
summarized the relative risk estimates for Caucasians for
three of the most frequent SE+ DRB1 alleles in the Cau-
casian population. The relative risk is 6 for the
DRB1*0401 allele, 5 for the DRB1*0404 allele and 1 for
the DRB1*0101 allele. Thus, while the relative risk for indi-
viduals carrying the DRB1*0401 allele or the *0404 allele
is approximately five times higher compared with that for
individuals not carrying these alleles, the DRB1*0101
allele does not confer risk on its own. It has been debated
whether the RA-associated DRB1 alleles are disease risk
genes or prognostic markers for a more progressive
disease course, and whether individuals carrying two SE+
DRB1 alleles either have a higher risk of developing
disease or develop more severe disease compared with
individuals with only one SE+ DRB1 allele (for recent
reviews, see for example [3,4]). So far, no consensus has
been reached in answering these questions, which have
been addressed most recently in an unselected popula-
tion based study of 680 new-onset cases with inflamma-
tory polyarthritis, of whom 404 fulfilled the American
College of Rheumatology (ARC) criteria for RA [5]. Such a
study seems optimal to answer these questions. The
study confirmed the association between RA and the
presence of any SE allele, and thus demonstrated that the
SE allele does in fact confer susceptibility to RA even
though the relative risk was modest (RR = 2.3). Both of
the two most frequent DRB1*04 alleles, *0401 andhttp://arthritis-research.com/content/2/3/208
*0404, were significantly associated with RA, and it was
noted that the *0404 allele apparently had the strongest
effect, but this point was not formally proven because the
relative risk values for these two alleles had overlapping
confidence limits. This study also provided evidence that
the risk conferred by carrying two SE+ DRB1 alleles was
only slightly greater than the risk conferred by carrying one
SE+ DRB1 allele, with the exception of SE+ combinations
that included the DRB1*0404 allele. However, the latter
interpretation was based on relatively few patients and
needs confirmation. Future follow-up studies of the Norfolk
cohort [5] will most likely provide important information
about the possible role of SE+ DRB1 alleles in the clinical
course of RA.
HLA-DR or HLA-DQ as the primary risk factor
for RA
On the basis of observations of experimental mouse
models of collagen-induced arthritis, Zanelli et al [6]
advanced the provocative hypothesis; that it is HLA-DQ
molecules that predispose to RA, whereas DR molecules
are either permissive or protective. In the first variant of
this hypothesis, it was proposed that it was the DQB1
locus which was responsible for the DQ association.
However, a comprehensive review of the literature
demonstrated that the DQB1 association with RA is sec-
ondary to the HLA-DRB1 association [7]. Zanelli et al [8]
subsequently introduced a revised version of the DQ-
association hypothesis. One of the cornerstones in this
hypothesis was the observation that individuals carrying
certain HLA-DQA1 alleles (DQA-RA) are highly suscepti-
ble to developing RA. Interestingly, these DQA alleles
were not investigated in the reported patients or con-
trols, but their presence or absence was deduced from
the presence of certain DRB1 and DQB1 alleles. On the
basis of these data we have tested the RA-association of
their DQA-RA alleles against the RA-association of the
SE alleles (see supplementary data below) using our
previously described method [9]. It was found that the
SE association is still significant when stratified for the
DQA1-RA allele combination, while the DQA1-RA com-
bination is not significant when stratified for SE, indicat-
ing that the association with SE is stronger than that for
the DQA1-RA allele combination. In a subsequent report,
Zanelli and coworkers [10] claim to find support for their
hypothesis by introducing a new variable: homozygosity
for some but not all of their DQA-RA markers. But
because these data are to some extent at variance with
their earlier ones, support for their hypothesis is not
evident and difficult to accept. Taken together, our analy-
ses do not support the idea that HLA-DQ molecules play
a major role in the general susceptibility to RA, and
demonstrate that the strongest association in RA is with
DRB1 genes rather than DQB1 or DQA1 genes. This
conclusion is further substantiated by three studies that
also found no support for HLA-DQ encoded susceptibil-
ity in RA patients from Germany [11], Holland [12] and
Australia [13].
HLA class II transgenic mice and RA
The molecular basis for the HLA-DRB1 association with
RA is still unclear. One prevailing hypothesis is that the
RA-associated HLA-DR molecules present self-antigens
to autoaggressive T cells, which subsequently induce an
inflammatory response that leads to the development of
arthritis. This hypothesis is based partly on the biological
role of MHC class II molecules in T cell dependent immu-
nity and the presence of T cells in the synovial compart-
ment, and partly on extrapolated data from other human
HLA class II associated autoimmune disorders such as
insulin-dependent diabetes mellitus and multiple sclerosis,
and the animal models for these diseases. However, the
sporadic evidence for the involvement of autoreactive
T cells in the pathogenesis of RA [14], probably reflects
several competing factors, some of which are related to
difficulties in sampling T cells from RA patients. First,
autoreactive T cells do not need to be present in large
numbers; second, sampling generally occurs considerably
after the inflammatory process has started, which excludes
the analysis of T cells that are short-lived and/or play a role
only in the initiation of the disease process; and third,
patients are often on multiple immunomodulatory medica-
tions that further complicate sampling and subsequent
analysis of T cell reactivity. Furthermore, it is likely that
several autoantigens are targeted by inflammatory attacks,
and that the relative involvement of these autoantigens
may change from patient to patient and within the individ-
ual patient as disease progresses [15].
To delineate the role of RA-associated DR molecules in
immune responses possibly related to RA in a less
complex biological setting than RA patients, transgenic
mice expressing DR4 (DRB1*0401) and DR1
(DRB1*0101) were generated [16,17]. It was initially
shown that the human class II molecules in the thymus
contributed to the selection of the mouse T cell reper-
toire, and in the peripheral lymphoid compartment medi-
ated T cell responses to different antigens upon
immunization. These studies demonstrated, therefore, for
the first time, that it is possible to generate functional
human MHC class II transgenic mice. Of more direct rele-
vance to RA, it was subsequently shown that these mice
were useful for identifying T cell epitopes in proteins such
as collagen type II (CII), which is a candidate autoantigen
in RA. The dominant DRB1*0401 and DRB1*0101
restricted T cell epitope in CII was shown to correspond
to residues 261–273 [18,19], which is interesting
because this epitope overlaps with the dominant CII
T cell epitope presented by the mouse MHC class II mol-
ecule, I-Aq, associated with collagen-induced arthritis
(CIA) [20,21]. Moreover, by defining MHC and T cell
receptor contacts in CII 261–273 peptide [22] and byArthritis Research    Vol 2 No 3 Fugger and Svejgaard
generating a molecular model of the DRB1*0401 mole-
cule in complex with this peptide [23], it was directly
demonstrated that the CII 261–273 peptide matches the
peptide binding specificity of RA-associated DR mole-
cules [24]. The important question then was whether the
CII 261–273 peptide is recognized by T cells from RA
patients. Two recent studies have investigated this, and
came to different conclusions [25,26].
In the first study [25], T cell proliferative responses to
native CII and a CII 255–275 peptide (including the
261–273 peptide) were examined in RA patients,
osteoarthritis (OA) patients and healthy controls. All med-
ications were stopped 48 h before study entry. Even
though the peripheral blood T cell responses to native CII
were modest, the stimulation indices and the fraction of
individuals with positive T cell responses were significantly
higher in the RA group than in the OA patients and the
healthy controls. Comparison of synovial fluid and periph-
eral blood samples from RA patients showed that T cell
responses to native CII and the CII peptide in general were
higher in synovial fluid than in peripheral blood, and that
there was a good correlation between the T cell responses
to CII and the CII peptide. Interestingly, those RA patients
with a positive T cell response to native CII often had a
shorter disease duration than those with negative
responses, and positive T cells responses to CII were sig-
nificantly enhanced in early disease (<3 years) compared
with late disease (>3 years). Whether this correlation also
extends to the CII peptide was not investigated, but is likely
to be the case because of the observed correlation
between T cell reactivity to native CII and the CII peptide.
In the second study, fluorescent, soluble CII 261–273
peptide–DRB1*0401 complexes (tetramers) were used to
search for CD4+ T cells in synovial fluid from RA patients
[26]. The tetramers were shown to stain DRB1*0401-
restricted and CII 261–273-specific T cell hybridomas in a
specific manner, but did not stain a detectable fraction of
synovial CD4+ T cells. This suggests that the major oligo-
clonal CD4+ T cell expansion set in joints from this group
of RA patients does not recognize the dominant CII
epitope. However, this may be partly due to the fact that
nearly all patients were on multiple immunomodulatory
medications on study entry, and partly due to a rather long
disease duration in this RA group (mean duration of
disease, 13.8 years; range, 5–28 years). It will be interest-
ing to see whether tetramer stainings of T cells from RA
patients with shorter disease duration give another result,
and also interesting to compare tetramer staining and
functional T cell assays directly.
Development of humanized animal models for RA
One of the goals in generating transgenic mice expressing
RA-associated DR molecules was to develop humanized
animal models for RA. Neither DRB1*0401 nor
DRB1*0101 transgenic mice develop spontaneous arthri-
tis [16,17], which, however, was expected as RA is a poly-
genic disease with genetic factors other than HLA class II.
In addition, undefined nongenetic factors are thought to
play an important role in the development of disease [4].
When DRB1*0401 [22,27] and DRB1*0101 transgenic
mice [19] are immunized with native CII emulsified in com-
plete Freund’s adjuvant, the majority of the animals develop
inflammatory arthritis, which has interesting similarities with
RA and is more or less indistinguishable from classical CIA
as seen in, for example, H-2q mice [28]. Somewhat surpris-
ingly, DRB1*0401 and DRB1*0101 transgenic mice seem
to be equally susceptible to CIA, which clearly is in con-
trast to the situation in humans, where DR4 is a stronger
RA-risk gene than DR1. Furthermore, both strains develop
severe arthritis, which is also at variance with the risk factor
situation for RA, where DRB1*0401 is associated with
more severe disease than DRB1*0101 [3]. A trivial expla-
nation for these discrepancies arises from the obvious fact
that CIA is a disease provoked by immunization with CII in
complete Freund’s adjuvant, and thus differs from RA. This
powerful arthritis induction scheme may override the differ-
ential risks and severities conferred by DRB1*0401 and
DRB1*0101 in humans, which may also depend on
complex interactions with proteins encoded by other (non-
HLA) loci. Such epistatic interactions are most likely diffi-
cult to reproduce in transgenic mice expressing a single
human disease-risk gene. These comparisons across the
species barrier demonstrate that one should be cautious in
extrapolating from humanized animal models of disease to
actual human diseases.
Another example of how cautious one should be in the
interpretation of results from humanized animal models
comes from a study on HLA-DQ8 transgenic mice [29].
These mice also develop a severe inflammatory arthritis
upon immunization with CII and complete Freund’s adju-
vant, which merely demonstrates that the DQ8 molecule is
permissive for CIA in mice. This observation, together with
additional data from nonhumanized animal models of CIA,
was taken as evidence for the hypothesis that DQ8 rather
than DR4 confers the strongest susceptibility to RA in the
DR4-DQ8 haplotype. As already discussed, this hypothe-
sis has very short roots in human genetics, and illustrates
that the development of humanized animal models should
be based on careful analyses of human genetics.
Conclusion
The development of humanized animal models for RA has
so far been shown to be a feasible approach, but, even
taken together, the models have added very little to our
understanding of this disease. The development of a new
generation of humanized models in which the RA-associ-
ated HLA class II transgenes are expressed more physio-
logically, and where additional RA susceptibility genes are
incorporated, combined with a better understanding of thenongenetic component of the disease will provide a more
optimal setting for mechanistic studies of the disease
process and, ultimately, the development of new drugs.
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Supplementary data
On the basis of Tables 2 and 3 in Zanelli et al [8], the RA-
association of the DQA-RA marker was tested against that
of the SE marker using a 2 × 4 table [9]. This procedure is
illustrated here in Tables 1 and 2 on Dutch patient and
control data from Zanelli et al [8]. It appears that both the
DQA-RA and SE markers are quite strongly associated
with RA. Stratification of the two markers shows that the
DQA-RA marker cannot be tested in SE-positive patients
and controls because all SE-positive individuals were also
DQA-RA-positive, leaving no information. When testing the
DQA-RA association in SE-negative patients and controls,
the association is no longer significant. Conversely, when
testing the SE association in DQA-RA-positive patients
and controls, it appears that this association is still signifi-
cant, indicating a stronger association with SE than with
DQA-RA. Unfortunately, the absolute inclusion of SE in
DQA-RA patients prohibits testing of SE in DQA-RA-nega-
tive individuals. When combining the data on Dutch people
with those on Swiss individuals in [8] in Table 3, the results
in Table 1 are further supported: the stratification proce-
dure gives only evidence for a stronger SE than a DQA-RA
association, and it may be noted that there is no significant
heterogeneity between the two data sets.
Table 1
A 2 × 4 table of DQA-RA and SE markers in Dutch patients with
RA and Dutch controls
DQA-RA SE Patients Controls
+ + 172 127
+– 7 1 9
–+ 0 0
– – 58 160
Total 237 306
Data from Zannelli et al [8]. DQA-RA, RA-associated DQA markers as
defined by Zanelli et al [8]; SE, shared epitope for RA-associated HLA-
DR markers.
Table 2
The 2 × 2 analyses [9] of the data in Table 1
Test Comparison a b c d Odds ratio Fisher’s P value
DQA-RA 179 58 146 160 3.4 3E-11
association
SE association 172 65 127 179 3.7 3E-13
DQA-RA association
in SE-positive ++ vs –+ 172 0 127 0 ND ND
DQA-RA association
in SE-negative +– vs –– 7 58 19 160 1.1 NS
SE association in
DQ-RA-positive ++ vs +– 172 7 127 19 3.5 0.0024; Pc = 0.029
SE association in
DQ-RA-negative –+ vs –– 0 58 0 160 ND ND
ND, Not defined; NS, not significant; Pc, corrected P value; a and b, numbers of patients with and without marker in question; c and d, numbers of
controls with and without marker in question.
Table 3
Combined analyses in 2 × 2 analyses of data in Table 1 and data on Swiss patients and controls given in Zanussi et al [8]
Test Odds ratio Significance* P Heterogeneity† P‡
DQA-RA association 3.4 90.5 2E-21 1.35 0.51
SE association 4.1 102.0 5E-24 0.62 0.74
DQA-RA association in SE-positive ND
DQA-RA association in SE-negative 1.5 1.7 0.19 1.2 0.54
SE association in DQ-RA-positive 2.9 12.7 0.0004 0.35 0.84
SE association in DQ-RA-negative ND
ND, Not defined. * Significance for the deviation of odds ratio from unity. † Heteroengeneity between the two sets of data. ‡ Significance for the
heterogeneity.